Rampal, Raajit K.

Publications

Sort by

Co-Author Network

selected publications

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Academic Article GET IT
Times cited: 97
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematological oncology. 2019 Review GET IT
Times cited: 7
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Academic Article GET IT
Times cited: 165
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood. 2018 Academic Article GET IT
Times cited: 29
Single-agent dabrafenib for BRAF^V600E-mutated histiocytosis. Haematologica. 2018 Academic Article GET IT
Times cited: 32
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood advances. 2018 Academic Article GET IT
Times cited: 91
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 56
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer cell. 2017 Academic Article GET IT
Times cited: 137
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 Academic Article GET IT
Times cited: 93
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica. 2017 Letter GET IT
Times cited: 15
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. 2017 GET IT
Times cited: 95
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017 Academic Article GET IT
Times cited: 86
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017 Academic Article GET IT
Times cited: 75
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell stem cell. 2017 Academic Article GET IT
Times cited: 92
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 2016 GET IT
Times cited: 52
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leukemia research. 2016 Academic Article GET IT
Times cited: 16
Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet journal of rare diseases. 2016 Letter GET IT
Times cited: 19
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. The Journal of experimental medicine. 2016 Academic Article GET IT
Times cited: 104
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia research. 2016 Academic Article GET IT
Times cited: 13
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Letter GET IT
Times cited: 27
Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. Mediterranean journal of hematology and infectious diseases. 2016 Academic Article GET IT
Times cited: 54
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica. 2016 Review GET IT
Times cited: 62
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2016 Review GET IT
Times cited: 5
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals of hematology. 2016 Letter GET IT
Times cited: 26
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. Haematologica. 2016 Letter GET IT
Times cited: 13
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Academic Article GET IT
Times cited: 208
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 49
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. The oncologist. 2015 Review GET IT
Times cited: 12
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood cancer journal. 2015 Academic Article GET IT
Times cited: 97
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer cell. 2015 Academic Article GET IT
Times cited: 110
Clinical and molecular genetic characterization of myelofibrosis. Current opinion in hematology. 2015 Review GET IT
Times cited: 15
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer discovery. 2015 Academic Article GET IT
Times cited: 212
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell reports. 2014 Academic Article GET IT
Times cited: 206
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 209
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2014 Review GET IT
Times cited: 3
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer discovery. 2014 Academic Article GET IT
Times cited: 105
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 2014 Academic Article GET IT
Times cited: 28
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014 Academic Article GET IT
Times cited: 176
Integrating genomics into prognostic models for AML. Seminars in hematology. 2014 Academic Article GET IT
Times cited: 6
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Best practice & research. Clinical haematology. 2014 Review GET IT
Times cited: 17
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 98
Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. British journal of haematology. 2014 Letter GET IT
Times cited: 23
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 Academic Article GET IT
Times cited: 310
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Current opinion in hematology. 2014 Review GET IT
Times cited: 29
Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature. Leukemia & lymphoma. 2014 Review GET IT
Times cited: 16
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014 Academic Article GET IT
Times cited: 89
Leveraging cancer genome information in hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Review GET IT
Times cited: 12
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. 2012 GET IT
Times cited: 3
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. 2012 GET IT
Times cited: 43
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 Academic Article GET IT
Times cited: 179
Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. The Journal of clinical investigation. 2011 Comment GET IT
Times cited: 3

more ...

less ...

Background

education and training

M.D., State University of New York at Stony Brook, School of Medicine 2007
Ph.D., State University of New York at Stony Brook 2005
B.S., University of Rochester 1999

Contact

full name

Raajit K. Rampal

VIVO Weill Cornell Medical College

Raajit K. Rampal Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name